Estrogenic Affinity Labels: Synthesis, Irreversible Receptor Binding, and Bioactivity of Aziridine-Substituted Hexestrol Derivatives

Jeffery A. Zablocki, John A. Katzenellenbogen, Kathryn E. Carlson, M. J. Norman, Benita S Katzenellenbogen

Research output: Contribution to journalArticle

Abstract

To develop an affinity label for the estrogen receptor that would be an estrogen agonist, rather than antagonist, we prepared several aziridine derivatives of the potent nonsteroidal estrogen hexestrol ((3R*,4S*)-3,4-bis(4-hydroxyphenyl)hexane) bearing an aziridine function on the side chain. Three functional groups link the hexestrol ligand and the aziridine: a carbonyl group (ketone or ester), a thioether, or a methylene chain. The apparent competitive binding affinity of these derivatives for the estrogen receptor ranges from 1.8% to 25% that of estradiol, and most of them bind in a time-dependent, irreversible manner with the receptor, although the rate and efficiency of this binding vary widely, often with relatively small changes in structure. This is consistent with the irreversible attachment requiring a precise alignment of activating and reacting residues in the binding site of the receptor. The estrogenic and antiestrogenic activity of these aziridine derivatives was investigated in MCF-7 human breast cancer cells. Most of the compounds are agonists, with one being an antagonist. The derivative (6R*,7S*)-1-N-aziridinyl-6,7-bis(4-hydroxyphenyl)-5-nonanone (keto-nonestrol aziridine 3) appears to have the most ideal behavior of the estrogenic affinity labeling agents prepared: It is an agonist, and it binds to receptor irreversibly, efficiently, and quite rapidly.

Original languageEnglish (US)
Pages (from-to)829-838
Number of pages10
JournalJournal of Medicinal Chemistry
Volume30
Issue number5
DOIs
StatePublished - May 1 1987
Externally publishedYes

Fingerprint

Hexestrol
Affinity Labels
Estrogen Receptors
Non-Steroidal Estrogens
Competitive Binding
Hexanes
Sulfides
Ketones
Estradiol
Estrogens
Esters
Binding Sites
aziridine
Breast Neoplasms
Ligands

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Estrogenic Affinity Labels : Synthesis, Irreversible Receptor Binding, and Bioactivity of Aziridine-Substituted Hexestrol Derivatives. / Zablocki, Jeffery A.; Katzenellenbogen, John A.; Carlson, Kathryn E.; Norman, M. J.; Katzenellenbogen, Benita S.

In: Journal of Medicinal Chemistry, Vol. 30, No. 5, 01.05.1987, p. 829-838.

Research output: Contribution to journalArticle

Zablocki, Jeffery A. ; Katzenellenbogen, John A. ; Carlson, Kathryn E. ; Norman, M. J. ; Katzenellenbogen, Benita S. / Estrogenic Affinity Labels : Synthesis, Irreversible Receptor Binding, and Bioactivity of Aziridine-Substituted Hexestrol Derivatives. In: Journal of Medicinal Chemistry. 1987 ; Vol. 30, No. 5. pp. 829-838.
@article{2c2478f43adb42bcb623b122c3795fa8,
title = "Estrogenic Affinity Labels: Synthesis, Irreversible Receptor Binding, and Bioactivity of Aziridine-Substituted Hexestrol Derivatives",
abstract = "To develop an affinity label for the estrogen receptor that would be an estrogen agonist, rather than antagonist, we prepared several aziridine derivatives of the potent nonsteroidal estrogen hexestrol ((3R*,4S*)-3,4-bis(4-hydroxyphenyl)hexane) bearing an aziridine function on the side chain. Three functional groups link the hexestrol ligand and the aziridine: a carbonyl group (ketone or ester), a thioether, or a methylene chain. The apparent competitive binding affinity of these derivatives for the estrogen receptor ranges from 1.8{\%} to 25{\%} that of estradiol, and most of them bind in a time-dependent, irreversible manner with the receptor, although the rate and efficiency of this binding vary widely, often with relatively small changes in structure. This is consistent with the irreversible attachment requiring a precise alignment of activating and reacting residues in the binding site of the receptor. The estrogenic and antiestrogenic activity of these aziridine derivatives was investigated in MCF-7 human breast cancer cells. Most of the compounds are agonists, with one being an antagonist. The derivative (6R*,7S*)-1-N-aziridinyl-6,7-bis(4-hydroxyphenyl)-5-nonanone (keto-nonestrol aziridine 3) appears to have the most ideal behavior of the estrogenic affinity labeling agents prepared: It is an agonist, and it binds to receptor irreversibly, efficiently, and quite rapidly.",
author = "Zablocki, {Jeffery A.} and Katzenellenbogen, {John A.} and Carlson, {Kathryn E.} and Norman, {M. J.} and Katzenellenbogen, {Benita S}",
year = "1987",
month = "5",
day = "1",
doi = "10.1021/jm00388a015",
language = "English (US)",
volume = "30",
pages = "829--838",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "5",

}

TY - JOUR

T1 - Estrogenic Affinity Labels

T2 - Synthesis, Irreversible Receptor Binding, and Bioactivity of Aziridine-Substituted Hexestrol Derivatives

AU - Zablocki, Jeffery A.

AU - Katzenellenbogen, John A.

AU - Carlson, Kathryn E.

AU - Norman, M. J.

AU - Katzenellenbogen, Benita S

PY - 1987/5/1

Y1 - 1987/5/1

N2 - To develop an affinity label for the estrogen receptor that would be an estrogen agonist, rather than antagonist, we prepared several aziridine derivatives of the potent nonsteroidal estrogen hexestrol ((3R*,4S*)-3,4-bis(4-hydroxyphenyl)hexane) bearing an aziridine function on the side chain. Three functional groups link the hexestrol ligand and the aziridine: a carbonyl group (ketone or ester), a thioether, or a methylene chain. The apparent competitive binding affinity of these derivatives for the estrogen receptor ranges from 1.8% to 25% that of estradiol, and most of them bind in a time-dependent, irreversible manner with the receptor, although the rate and efficiency of this binding vary widely, often with relatively small changes in structure. This is consistent with the irreversible attachment requiring a precise alignment of activating and reacting residues in the binding site of the receptor. The estrogenic and antiestrogenic activity of these aziridine derivatives was investigated in MCF-7 human breast cancer cells. Most of the compounds are agonists, with one being an antagonist. The derivative (6R*,7S*)-1-N-aziridinyl-6,7-bis(4-hydroxyphenyl)-5-nonanone (keto-nonestrol aziridine 3) appears to have the most ideal behavior of the estrogenic affinity labeling agents prepared: It is an agonist, and it binds to receptor irreversibly, efficiently, and quite rapidly.

AB - To develop an affinity label for the estrogen receptor that would be an estrogen agonist, rather than antagonist, we prepared several aziridine derivatives of the potent nonsteroidal estrogen hexestrol ((3R*,4S*)-3,4-bis(4-hydroxyphenyl)hexane) bearing an aziridine function on the side chain. Three functional groups link the hexestrol ligand and the aziridine: a carbonyl group (ketone or ester), a thioether, or a methylene chain. The apparent competitive binding affinity of these derivatives for the estrogen receptor ranges from 1.8% to 25% that of estradiol, and most of them bind in a time-dependent, irreversible manner with the receptor, although the rate and efficiency of this binding vary widely, often with relatively small changes in structure. This is consistent with the irreversible attachment requiring a precise alignment of activating and reacting residues in the binding site of the receptor. The estrogenic and antiestrogenic activity of these aziridine derivatives was investigated in MCF-7 human breast cancer cells. Most of the compounds are agonists, with one being an antagonist. The derivative (6R*,7S*)-1-N-aziridinyl-6,7-bis(4-hydroxyphenyl)-5-nonanone (keto-nonestrol aziridine 3) appears to have the most ideal behavior of the estrogenic affinity labeling agents prepared: It is an agonist, and it binds to receptor irreversibly, efficiently, and quite rapidly.

UR - http://www.scopus.com/inward/record.url?scp=0023177450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023177450&partnerID=8YFLogxK

U2 - 10.1021/jm00388a015

DO - 10.1021/jm00388a015

M3 - Article

C2 - 3033242

AN - SCOPUS:0023177450

VL - 30

SP - 829

EP - 838

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 5

ER -